用于治疗阿尔茨海默氏病的氨酸衍生物
Branislav Pavilek1, Dana Hajduová1, Dušan Bortňák1
1Institute of Organic Chemistry, Catalysis, and Petrochemistry, Faculty of Chemical and Food Technology, Slovak University of Technology, Radlinského 9, SK-812 37 Bratislava, Slovakia.
Bioorganic & medicinal chemistry
|February 19, 2026
概括
氨酸 (KYNA) 胺基显示出作为阿尔茨海默病 (AD) 多重向药物 (MTDD) 的前景. 像化合物7和8这样的衍生品通过解决多个AD标志提供了广泛的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 阿尔茨海默病 (AD) 迫切需要新的治疗策略.
- 氨酸 (KYNA) 具有固有的神经保护和抗炎性质,使其成为AD药物开发的候选药物.
- 基纳衍生物,特别是胺,正在成为针对阿尔茨海默病等复杂疾病的多向药物 (MTDD).
研究的目的:
- 审查KYNA衍生物,重点关注KYNA胺作为阿尔茨海默病潜在的MTDD.
- 为了总结KYNA支架的实验室合成路线.
- 批判性地评估有希望的KYNA衍生物的药理学概况和生物试验结果.
主要方法:
- 关于KYNA衍生物及其合成的综合文献综述.
- 对已识别的KYNA衍生物 (化合物1-11) 的生物试验数据的分析.
- 在体外和体内疗效的评估,包括像Caenorhabditis elegans这样的模型.
主要成果:
- 确定了11种主要的KYNA衍生品 (化合物1-11),具有MTDD概况.
- 化合物2和6在Caenorhabditis elegans模型中表现出体内有效性.
- 化合物7和8表现出高强度,调节了五个AD特征:Aβ聚合,氧化应激,神经递质失衡,神经炎症和促进神经发生.
结论:
- 基纳氨基体代表阿尔茨海默病的MTDD的一个有前途的类别.
- 氨基化是开发基于KYNA的MTDD与量身定制的药理活动的关键合成策略.
- 化合物7和8显示出显著的疾病修饰潜力,解决了AD的多种病理方面.
相关概念视频
01:22Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
696
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
696
01:24Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
01:26Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
01:23Antidepressant Drugs: MAOIs and Other Agents
991
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
991
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.7K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K